Ultra-Strong
Twice as strong as other artificial spider silks, offering unmatched durability and performance.
Flexible
Exhibit nearly double the extensibility in high-humidity conditions compared to natural flagelliform silk.
Adaptable
Can be crosslinked with ingredients like antibiotics to create tailored biomaterials.
Welcome to PrintyMed
At PrintyMed, we are shaping the future of medicine and materials through the groundbreaking potential of biomimetic spider silk.
What makes PrintyMed unique is our precision engineering, delivering high-performance solutions designed for groundbreaking medical advancements.
At the same time, our sustainable and scalable production methods offer an eco-friendly alternative to synthetic materials, minimizing environmental impact without compromising quality.
By blending nature’s brilliance with cutting-edge science, we are driving medical breakthroughs that improve lives and reshape industries.
About Us
PrintyMed was born from a shared vision to bridge the gap between groundbreaking science and real-world medical applications. Established in January 2023 by three co-founders with expertise in organic chemistry, business strategy, and medicine, our company stands at the crossroads of innovation and practicality.
We collaborate closely with the Latvian Institute of Organic Synthesis, leveraging its state-of-the-art biomimetic spider silk technology to develop solutions that transform patient care and enhance industry standards. Each member of our founding team brings a unique perspective, combining scientific rigor, entrepreneurial insight, and a deep understanding of medical needs to shape the future of biomedicine.
Our mission is not just about creating materials — it’s about redefining possibilities. Whether it’s replacing invasive procedures with advanced prostheses, accelerating research with organ-on-a-chip membranes, or crafting sustainable beauty products, PrintyMed is driven by the desire to improve lives.
Our Technology: Pioneering Innovation
At the heart of PrintyMed is our proprietary biomimetic spider silk technology, developed in collaboration with the Latvian Institute of Organic Synthesis. Engineered to replicate the natural spinning process of spider silk, our technology combines advanced protein engineering and scalable production methods to achieve extraordinary results.
Key Features of Biomimetic Spider Silk Technology
Unmatched Strength and Flexibility
Ideal for medical applications requiring robust yet adaptable materials.
Customizable
Properties
Silk fibers can be tailored to specific applications, ensuring optimal performance in diverse industries.
Non-animal-based
Our material is produced in bacteria without employing any animal-based material.
Biocompatibility
at its Core
Facilitates cell adhesion, regeneration, and integration into human tissues.
Sustainable and
Eco-Friendly
Our process uses water as the sole solvent, eliminating pollution and reducing environmental impact.
Our Breakthrough Production Process
Protein Design and Synthesis
Dope Formation
Fiber Spinning
Industrial Scalability
Leveraging biomimetic principles, we engineer proteins with optimal structural and functional properties.
Proteins are processed into dope that serve as the foundation for spinning silk fibers.
Our advanced biomimetic spinning method replicates the natural process, producing fibers with unparalleled strength and elasticity.
A scalable manufacturing technology has been developed in lab-scale bioreactors applicable for industrial applications.
Our Solutions
1. Organs-on-a-Chip Membranes
Accelerating research and innovation, our membranes are a game-changer for drug screening, disease modeling, and future food testing. Engineered from biomimetic spider silk, they provide unmatched support for cell cultures in microfluidic environments.
2. Cosmetic Ingredients
Our biomimetic spider silk proteins bring regenerative properties to the world of high-end cosmetics. As a sustainable and innovative raw material, it enables groundbreaking formulations for skincare and haircare professionals.
3. Heart Valve Prostheses
We are pioneering durable and biocompatible heart valve prostheses made from biomimetic spider silk. By addressing the limitations of current solutions, our valves promise longer lifespans, reduced clot risks, and fewer invasive surgeries.
4. Advanced Wound Dressings
Leveraging the exceptional properties of biomimetic spider silk, PrintyMed is creating next-generation wound dressings that offer superior healing capabilities. These dressings promote cell regeneration, reduce infection risks, and provide unparalleled comfort and adaptability. Ideal for chronic wounds, burns, and surgical applications, our solutions represent a significant leap forward in wound care technology.
5. Artificial Organs and Scaffolds
Harnessing the potential of biomimetic spider silk, PrintyMed is advancing the development of artificial organs and scaffolds to address the global shortage of transplantable organs. Our silk’s unparalleled cell adhesion and customization capabilities enable the creation of biocompatible, patient-specific solutions. These innovations promise to redefine regenerative medicine and improve the quality of life for millions worldwide.
Why Choose PrintyMed?
1
Our solutions redefine industry standards, offering unrivaled performance and sustainability.
Innovation-Driven
2
Partnering with innovative companies and research centres in biotech, cosmetics, and medical technology.
Collaborative Approach
3
Made from renewable resources. We offer proteins, hydrogel, and fibers for medical and cosmetic industries, ensuring zero waste.
Future-Focused
The Founders
Dedication. Expertise. Passion.
Jekaterina Romanova
CEO
Experienced serial entrepreneur.
With over 10 years in the medical deep-tech sector, has founded and developed multiple startups.
Holding a Master’s degree in Economics and expertise in European project management.
Actively engaged in the startup ecosystem as a mentor and lecturer.
Prof. Gints Smits
CTO
Head of the Laboratory at Latvian Institute of Organic Synthesis.
For more than 7 years in spider silk research.
Got Latvian Academy of Sciences diploma for one of most significant science achievements in Latvia in 2024.
Dr. Sandra Treide
CMO
Seasoned medical with over 25 years of experience in the pharmaceutical industry.
Specializing in the commercialization of innovative medical technologies and devices.
Successfully transitioned two groundbreaking medical technologies from university research to industry application.
PhD Viktors
Romanuks
COO
Scientist at Latvian Institute of Organic Synthesis.
For more than 5 years in spider silk research.
Got Latvian Academy of Sciences diploma for one of most significant science achievements in Latvia in 2024.
Prof. Kristaps Jaudzems
Founder
Dean of the Faculty of Medicine and Life Sciences at University of Latvia.
For more than 10 years in spider silk research.
Got Latvian Academy of Sciences diploma for one of most significant science achievements in Latvia in 2017, 2021 and 2024.
Most significant achievement in Latvian science 2024
Our Publications
(23.03.2022.) Engineered Spider Silk Proteins for Biomimetic Spinning of Fibers with Toughness Equal to Dragline Silks Tina Arndt, Gabriele Greco, Benjamin Schmuck, Jessica Bunz, Olga Shilkova, Juanita Francis, Nicola M Pugno, Kristaps Jaudzems, Andreas Barth, Jan Johansson, and Anna Rising* - Advanced Functional Materials; https://doi.org/10.1002/adfm.202200986
(07.04.2022.) The dimerization mechanism of the N-terminal domain of spider silk proteins is conserved despite extensive sequence divergence; Médoune Sarr1 , Kristine Kitoka2 , Kellie-Ann Walsh-White1 , Margit Kaldmäe3 , Rimants Metlans2 , Kaspar Tars4 , Alessandro Mantese5 , Dipen Shah5 , Michael Landreh3 , Anna Rising6,7 , Jan Johansson1,7, Kristaps Jaudzems2,*, and Nina Kronqvist1,7,*; Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology, https://doi.org/10.1016/j.jbc.2022.101913;
(14.06.2022.) Solution Structure of Tubuliform Spidroin N-Terminal Domain and Implications for pH Dependent Dimerization; Megija Šede, Jēkabs Fridmanis , Martins Otikovs 1 , Jan Johansson , Anna Rising , Nina Kronqvist and Kristaps Jaudzems*; Frontiers in Molecular Biosciences; https://doi.org/10.3389/fmolb.2022.936887;
(15.08.2022.) Spidroin N-terminal domain forms amyloid like fibril based hydrogels and provides a protein immobilization platform; Tina Arndt , Kristaps Jaudzems, Olga Shilkova , Juanita Francis, Mathias Johansson , Peter R. Laity, Cagla Sahin , Urmimala Chatterjee , Nina Kronqvist, Edgar Barajas-Ledesma, Rakesh Kumar , Gefei Chen , Roger Strömberg , Axel Abelein , Maud Langton , Michael Landreh , Andreas Barth, Chris Holland , Jan Johansson1 & Anna Rising ; https://doi.org/10.1038/s41467-022-32093-7
Let's redefine the future of biomedicine together!
We’re here to collaborate, innovate, and inspire.
Reach out to us today to learn more about how PrintyMed’s biomimetic spider silk solutions can transform your industry.
Follow Us
Stay updated with our latest innovations, news, and events.
SIA PrintyMed
Reg. No. 40203456040
Awards & programs
